<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>前免疫</title><link/>https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;utm_campaign=journals&amp;utm_source=Chrome&amp;fc=None&amp;utm_content=101560960&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;ff=20250214071914<description>前免疫：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;utm_campaign=journals&amp;utm_source=Chrome&amp;fc=None&amp;utm_content=101560960&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;ff=20250214071914" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate>星期五，2025年2月14日12:19:16 +0000</lastbuilddate><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>用活性维生素D3补充，通过调节肌功能性T细胞亚群的分化和功能来改善小鼠中实验性自身免疫性甲状腺炎</title><link/>https://pubmed.ncbi.nlm.nih.gov/39949783/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250214071914&amp;v=2.18.0.post9+e462414<description>结论：补充维生素D3可以有效治疗小鼠的自身免疫性甲状腺炎。 VD3通过抑制促炎TFH，TH17，TH1和TH2细胞的分化和功能，并促进抗炎B10细胞和Treg的分化和功能，从而减少了自身免疫性甲状腺损伤并降低小鼠血清甲状腺抗体水平。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月30日； 16：1528707。 doi：10.3389/fimmu.2025.1528707。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：桥本甲状腺炎（HT）的患者通常具有低维生素D3浓度。一些研究表明，补充维生素D3可减少甲状腺炎症，但这仍然有争议。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在雌性点头/shiltj小鼠中诱导EAT，通过给它们含有0.05％碘钠的水，每隔一天将1α，25-（OH） <sub>2</sub> D <sub>3</sub>的1μg/kg诱导。 8周后，通过组织学切片，甲状腺自身抗体和甲状腺激素浓度检查小鼠甲状腺卵泡的形态结构，通过酶 - 连接的免疫吸附测定法（ELISAS）以及B-和T-番茄的主要功能和亚基确定通过组织多重免疫荧光技术和ELISA确定小鼠甲状腺。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：EAT在小鼠中引起甲状腺炎的卵泡破坏和流体淋巴细胞浸润，循环甲状腺自身免疫性抗体TG-AB和TPO-AB的浓度增加，以及甲状腺激素的异常。 EAT还增加了甲状腺中CD4+ TFH，Th17，Th1和Th2细胞的数量和功能，同时减少CD4+ Treg细胞和CD19 <sup>+</sup> B10细胞的数量和功能。用VD3处理逆转了这些变化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：补充维生素D3可以有效治疗小鼠的自身免疫性甲状腺炎。 VD3通过抑制促炎TFH，TH17，TH1和TH2细胞的分化和功能，降低小鼠血清甲状腺抗体水平的降低，并通过促进抗炎B10细胞和Treg的分化和功能。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39949783/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">39949783</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11821646/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">PMC11821646</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1528707>10.3389/fimmu.2025.1528707</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39949783</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Chun-Mei Wang</dc:creator><dc:creator> Ying-Jie Chen</dc:creator><dc:creator> Bo-cheng Yang</dc:creator><dc:creator> Jia-wen Yang</dc:creator><dc:creator>魏王</dc:creator><dc:creator>杨Zeng</dc:creator><dc:creator>江江</dc:creator><dc:date>2025-02-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>用活性维生素D3补充，通过调节肌功能性T细胞亚群的分化和功能来改善小鼠中实验性自身免疫性甲状腺炎</dc:title><dc:identifier>PMID：39949783</dc:identifier><dc:identifier> PMC：PMC11821646</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1528707</dc:identifier></item><item><title>探索肺癌自身抗体降低的诊断和预后作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/39949782/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250214071914&amp;v=2.18.0.post9+e462414<description>结论：我们证实了自身抗体在肺癌中的重要性，提供了新的诊断和治疗策略。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月30日； 16：1538071。 doi：10.3389/fimmu.2025.1538071。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：肿瘤相关抗原（TAA）是在肿瘤细胞生长和发育过程中表达的蛋白质，可以在肺癌患者的血清中检测到TAA自身抗体（TAAB），可用于早期筛查肺癌。几乎所有用于诊断的TAAB均为升高的TAAB，但是仍然发现大量自身抗体可降低肿瘤血清的降低，并且它们的功能很少是已知的。在CT扫描中诊断恶性小肺结节（≤3cm）仍然是临床实践中的挑战。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在这项研究中，我们应用了Huprot阵列和生物信息学分析来评估肺癌自身抗体降低的诊断值。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：总共确定了15种降低自身抗体的类型，其中6个被构建为早期肺癌的预测模型，敏感性为76.19％，特异性为55.74％。我们与4个升高的TAAB相结合，10标记模型的灵敏度和特异性分别可以达到80.0％和87.0％，这比早期肺癌诊断中常用的7-TAABS模型的灵敏度和87.0％高。此外，还可以使用5次自身抗体来监督肺腺癌中的骨转移。 13例被诊断出患有早期肺癌的患者的后续过程表明，在切除肿瘤后，15例自身抗体中有10例降低的自身抗体将恢复到更高的水平。生物信息学分析表明，这15种生物标志物与肺癌患者的预后密切相关。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们证实了自身抗体在肺癌中的重要性，提供了新的诊断和治疗策略。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39949782/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">39949782</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11821978/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">PMC11821978</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1538071>10.3389/fimmu.2025.1538071</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39949782</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator>是的</dc:creator><dc:creator>Yi Huang</dc:creator><dc:creator>江锅</dc:creator><dc:date>2025-02-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>探索肺癌自身抗体降低的诊断和预后作用</dc:title><dc:identifier>PMID：39949782</dc:identifier><dc:identifier> PMC：PMC11821978</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1538071</dc:identifier></item><item><title>鉴定和验证新型自身抗体生物标志物面板，用于胰腺导管腺癌的鉴别诊断</title><link/>https://pubmed.ncbi.nlm.nih.gov/39949781/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250214071914&amp;v=2.18.0.post9+e462414<description>结论：因此，该AAB面板可能有可能构成PDAC的新诊断测试的基础。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月30日； 16：1494446。 doi：10.3389/fimmu.2025.1494446。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：迫切需要新的生物标志物在早期阶段检测胰腺导管腺癌（PDAC）以进行个性化治疗策略并改善结果。自身抗体（AABS）原则上使疾病早期出现时会产生吸引人的生物标志物，报道了与疾病相关的细胞蛋白质组织扰动的报道，并且可以响应其他常见刺激而静止，但在外围却是可以衡量的，可能会在开始时就可以衡量。临床症状。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在这里，我们使用高通量，定制的癌症抗原微阵列来识别能够差异检测PDAC的临床相关自身抗体生物标志物组合。具体而言，我们量化了94个PDAC，慢性胰腺炎（CP），其他胰腺（PC）和前列腺癌（PRC）（PRC），非胰腺抑制患者（DYS）（DYS）和健康对照（HC）（HC）的血清学AAB谱。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：来自癌症抗原微阵列的训练队列数据的组合ROC曲线分析，将最有效的生物标志物组合确定为CeCAM1-DPPA2-DPPA3-DPPA3-MAGEA4-SRC-TPBG-XAGE3，AUC = 85·0％（SE = 0·828·828·828·0·（SE）） ，sp = 0·684）。此外，在Iome™阵列上运行的样品上的差异表达分析鉴定出PDAC中针对患病和健康对照的PDAC中上调的4个生物标志物（ALX1-GPA33-LIP1-SUB1）。使用公共免疫组织化学数据集对鉴定的AAB进行了验证，并使用包括11个最佳AAB AAB生物标志物面板的自定义PDAC蛋白微阵列进行了实验。在一个独立的队列中测试了生物标志物面板的临床实用性，其中包括223 PDAC，PC，PRC，大肠癌（CRC）和HC样品。关于验证数据的组合ROC曲线分析确定了最有效的生物标志物组合是CeCAM1-DPPA2-DPPA3-MAGEA4-SRC-TPBG-XAGE3，AUC = 85·0％（SE = 0·828，SP = 0·684） 。随后，对其他癌症（PDAC vs PC：AUC = 70·3％; PDAC vs CRC：AUC = 84·3％; PDAC vs PRC：AUC = 80·2％）和AUC = 80·2％）和健康对照（PDAC与HC：AUC = 80·9％），证实了该新型AAB生物标志物面板能够在其他混杂疾病中选择性检测PDAC。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：因此，该AAB面板可能有可能构成PDAC的新诊断测试的基础。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39949781/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">39949781</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11821970/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">PMC11821970</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1494446>10.3389/fimmu.2025.1494446</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39949781</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Metoboroghene O Mowoe</dc:creator><dc:creator>希沙姆·阿拉姆（Hisham Allam）</dc:creator><dc:creator>约书亚·恩卡达（Joshua Nqada）</dc:creator><dc:creator>马克·伯尔农</dc:creator><dc:creator>卡兰·甘地（Karan Gandhi）</dc:creator><dc:creator>肖恩·伯梅斯特（Sean Burmeister）</dc:creator><dc:creator>乌尔达·科兹（Urda Kotze）</dc:creator><dc:creator> Miriam Kahn</dc:creator><dc:creator>克里斯托·克洛普斯（Christo Kloppers）</dc:creator><dc:creator> Suba Dharshanan</dc:creator><dc:creator> Zafirah azween</dc:creator><dc:creator>帕梅拉·迈梅拉（Pamela Maimela）</dc:creator><dc:creator>保罗·汤森（Paul Townsend）</dc:creator><dc:creator>爱德华·乔纳斯（Eduard Jonas）</dc:creator><dc:creator>乔纳森·布莱克本（Jonathan M Blackburn）</dc:creator><dc:date> 2025-02-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>鉴定和验证新型自身抗体生物标志物面板，用于胰腺导管腺癌的鉴别诊断</dc:title><dc:identifier>PMID：39949781</dc:identifier><dc:identifier> PMC：PMC11821970</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1494446</dc:identifier></item><item><title>妇科恶性肿瘤中的CGA/刺激信号通路：从分子机制到治疗值</title><link/>https://pubmed.ncbi.nlm.nih.gov/39949780/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250214071914&amp;v=2.18.0.post9+e462414<description>妇科癌症，包括宫颈，卵巢和子宫内膜恶性肿瘤，仍然是全球重大的健康负担，这会因获得HPV疫苗接种和常规筛查等预防措施的差异而加剧。 CGA/STING信号通路是先天免疫中的关键机制，可检测来自病原体或细胞损伤的胞质DNA，通过I型干扰素和炎症细胞因子触发免疫反应。该途径在妇科癌症中的双重作用，要么... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月30日； 16：1525736。 doi：10.3389/fimmu.2025.1525736。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">妇科癌症，包括宫颈，卵巢和子宫内膜恶性肿瘤，仍然是全球重大的健康负担，这会因获得HPV疫苗接种和常规筛查等预防措施的差异而加剧。 CGA/STING信号通路是先天免疫中的关键机制，可检测来自病原体或细胞损伤的胞质DNA，通过I型干扰素和炎症细胞因子触发免疫反应。该途径在妇科癌症中的双重作用，促进抗肿瘤免疫或促进肿瘤免疫逃避，使其成为创新疗法的引人注目的靶标。该文章概述了CGAS/Sting对肿瘤微环境，免疫监测和炎症的影响，重点是推动癌症进展的分子机制。它探讨了DNA损伤反应途径与免疫调节之间的相互作用，突出了CGA/STING激活或抑制在卵巢，宫颈和子宫内膜癌中的影响。审查了刺激激动剂，PARP抑制剂和靶向免疫疗法的治疗潜力，证明了这些方法如何增强免疫反应，抵消化学疗法的耐药性并改善患者的结果。该研究还讨论了利用CGA/STING信号传导增强免疫疗法的功效并解决肿瘤介导的免疫抑制的策略，从而提供了对个性化癌症治疗的未来方向的见解。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39949780/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">39949780</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11821648/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">PMC11821648</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1525736>10.3389/fimmu.2025.1525736</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39949780</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Danyang Zhang</dc:creator><dc:creator> Bingxue Zhang</dc:creator><dc:date> 2025-02-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>妇科恶性肿瘤中的CGA/刺激信号通路：从分子机制到治疗值</dc:title><dc:identifier>PMID：39949780</dc:identifier><dc:identifier> PMC：PMC11821648</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1525736</dc:identifier></item><item><title>通过免疫检查点抑制剂治疗的肺癌患者中预测免疫介导的结肠炎的诺明图的开发和验证：中国的回顾性队列研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/39949779/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250214071914&amp;v=2.18.0.post9+e462414<description>结论：这项研究确定了肺癌患者IMC发展的八个独立预测指标，并随后开发了一种基于诺克图的预测模型来评估IMC风险。该模型的利用有可能协助临床医生实施适当的预防和治疗策略，最终导致该患者人群中IMC发病率的降低。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月30日； 16：1510053。 doi：10.3389/fimmu.2025.1510053。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：免疫检查点抑制剂（ICI）的使用增加导致免疫相关不良事件（IRAE）的发生率伴随着伴随的升高，尤其是免疫介导的结肠炎（IMC）。这项研究旨在确定与肺癌患者IMC发展相关的临床风险因素，并开发出促进个性化治疗和护理策略的风险预测模型。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：收集的数据包括21个变量，包括社会人口统计学特征，与癌症相关的因素和常规血液标记。将数据集随机分配为训练集（70％）和验证集（30％）。进行了单变量和多元逻辑回归分析，以识别IMC开发的独立预测指标。根据多变量分析的结果，开发了一个列图预测模型。通过接收器操作特征曲线（AUC），校准曲线分析，决策曲线分析（DCA）和临床影响曲线（CIC）评估模型性能。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在2103名患者中，有66名（3.14％）发展了IMC。多元逻辑回归分析表明，女性性别，小细胞肺癌（SCLC），β2微球蛋白（β2-MG）和球球蛋白（GLB）水平升高，中性粒细胞淋巴细胞比（NLR）作为IMC发展的独立预测因子（所有P）（所有<i>P）</i> &lt;0.05）。相反，将较高的白血细胞（WBC）计数，CD4/CD8比和血小板 - 淋巴细胞比（PLR）鉴定为与IMC发展风险降低相关的因素（所有<i>P</i> &lt;0.05）。命名预测模型表现出良好的歧视，在验证集中，训练集中的AUC达到了0.830（95％CI：0.774-0.887），在验证集中达到0.827（95％CI：0.709-0.944）。对校准曲线，DCA和CIC的分析表明，开发模型的良好预测准确性和临床实用性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项研究确定了肺癌患者IMC发展的八个独立预测指标，并随后开发了一种基于诺克图的预测模型来评估IMC风险。该模型的利用有可能协助临床医生实施适当的预防和治疗策略，最终导致该患者人群中IMC发病率的降低。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39949779/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">39949779</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11821966/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">PMC11821966</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1510053>10.3389/fimmu.2025.1510053</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39949779</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Qianjie Xu</dc:creator><dc:creator> li</dc:creator><dc:creator> Yuliang Yuan</dc:creator><dc:creator>广方梁</dc:creator><dc:creator>Zuhai Hu</dc:creator><dc:creator> Wei Zhang</dc:creator><dc:creator>王王</dc:creator><dc:creator>haike lei</dc:creator><dc:date> 2025-02-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>通过免疫检查点抑制剂治疗的肺癌患者中预测免疫介导的结肠炎的诺明图的开发和验证：中国的回顾性队列研究</dc:title><dc:identifier>PMID：39949779</dc:identifier><dc:identifier> PMC：PMC11821966</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1510053</dc:identifier></item><item><title>恢复17型免疫信号传导在与流感相关的肺曲霉病期间不足以保护</title><link/>https://pubmed.ncbi.nlm.nih.gov/39949778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250214071914&amp;v=2.18.0.post9+e462414<description>简介：与单独的患者相比，与流感的患者相比，与流感相关的肺曲霉病（IAPA）是一种严重的流感并发症，与单独的流感感染相比，死亡率更高。白介素17（IL-17）和17型免疫信号通路细胞因子家族在促进针对各种病原体的保护性免疫方面的关键作用被认可。在这项研究中，我们研究了IL-17和17型免疫信号传导成分的作用。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月30日； 16：1529849。 doi：10.3389/fimmu.2025.1529849。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：与单独的患者相比，与流感的患者相比，与流感相关的肺曲霉病（IAPA）是一种严重的流感并发症，与单独的流感感染相比，死亡率更高。白介素17（IL-17）和17型免疫信号通路细胞因子家族在促进针对各种病原体的保护性免疫方面的关键作用被认可。在这项研究中，我们研究了IAPA期间IL-17和17型免疫信号传导成分的作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：野生型小鼠受到流感A H1N1（流感）的挑战，然后在第6天暴露于Influenza感染后第6天静息<i>CCC42202</i> ATCCC42202静息肌，然后在感染后48小时对细胞因子和趋化因子进行量化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果和讨论：与仅用富灵<i>曲霉</i>的小鼠相比，在IAPA期间，IL-17和17型免疫细胞因子和抗菌肽的基因和蛋白质表达水平被下调。 17型免疫力的恢复不足以防止IAPA期间观察到的真菌负担增加。这些发现对比了，在细菌后超级感染期间观察到的发现，其中17型免疫信号传导的恢复可防止超级感染期间看到的加剧。我们的研究强调了未来研究的必要性，以了解增加对真菌感染敏感性的免疫机制。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39949778/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">39949778</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11821594/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">PMC11821594</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1529849>10.3389/fimmu.2025.1529849</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39949778</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Aijaz Ahmad</dc:creator><dc:creator> Ravineel B Singh</dc:creator><dc:creator> Kara L Nickolich</dc:creator><dc:creator> Matthew J Pilewski</dc:creator><dc:creator> Caden Ngeow</dc:creator><dc:creator> kwame frempong-manso</dc:creator><dc:creator>凯文·罗宾逊（Keven M Robinson）</dc:creator><dc:date> 2025-02-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>恢复17型免疫信号传导在与流感相关的肺曲霉病期间不足以保护</dc:title><dc:identifier>PMID：39949778</dc:identifier><dc:identifier> PMC：PMC11821594</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1529849</dc:identifier></item><item><title>免疫细胞在胃癌患者的乳状乳白点中的特征和临床意义</title><link/>https://pubmed.ncbi.nlm.nih.gov/39949777/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250214071914&amp;v=2.18.0.post9+e462414<description> omentum是包括胃癌在内的各种癌症中腹膜转移的常见部位。它包含称为乳白色斑点的免疫细胞聚集体，通过调节先天和适应性免疫反应，可为腹膜免疫提供微环境。在这项研究中，我们通过RNA测序分析研究了来自胃癌患者的昏性乳状斑点（n = 37）细胞中的基因表达谱，并将患者分为四组（G1-4）。值得注意的是，重要... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月30日； 16：1521278。 doi：10.3389/fimmu.2025.1521278。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> omentum是包括胃癌在内的各种癌症中腹膜转移的常见部位。它包含称为乳白色斑点的免疫细胞聚集体，通过调节先天和适应性免疫反应，可为腹膜免疫提供微环境。在这项研究中，我们通过RNA测序分析研究了来自胃癌患者的昏性乳状斑点（n = 37）细胞中的基因表达谱，并将患者分为四组（G1-4）。值得注意的是，两组之间在宏观类型，淋巴入侵，静脉侵袭和病理阶段（PSTAGE）方面观察到了显着差异。 G3富含与获得免疫相关的基因，显示出较早的肿瘤阶段（宏观0型，LY0，V0和Pstage I），并且预后更好。相比之下，G4显示出与中性粒细胞和先天免疫相关的基因富集。 G1和G2没有富集先天或适应性免疫相关的基因，这表明是一种免疫沙漠的微环境。细胞仪分析显示，G3中的T和B细胞明显更少，中性粒细胞较少。因此，在胃癌进展的阶段，昏迷斑点的免疫微环境可能会有所不同。当使用单变量COX比例危害回归模型来搜索特异性G3的预后相关基因时，将23个潜在的预后基因鉴定为与无复发生存和整体生存有关的共同基因。此外，使用这些预后基因和临床病理学信息的多元COX比例危害模型表明，将B细胞标记<i>CD19</i>和LY结合起来具有很高的预后预测精度。基于这项研究的结果，肿瘤进展，例如肿瘤细胞的淋巴和/或静脉浸润，可能会影响胃癌患者的乳状乳状斑点的免疫细胞组成和比例，并分析浮骨乳胶中基因表达斑点可能有助于预测胃癌预后。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39949777/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">39949777</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11821591/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">PMC11821591</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1521278>10.3389/fimmu.2025.1521278</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39949777</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Yasunobu Mano</dc:creator><dc:creator> Yuka Igarashi</dc:creator><dc:creator> Keisuke Komori</dc:creator><dc:creator> itaru hashimoto</dc:creator><dc:creator> Hayato Watanabe</dc:creator><dc:creator>高桥kosuke</dc:creator><dc:creator> Kazuki Kano</dc:creator><dc:creator>藤川岛</dc:creator><dc:creator>山田塔卡诺布</dc:creator><dc:creator>hidetomo himuro</dc:creator><dc:creator> Taku Kouro</dc:creator><dc:creator> Feifei Wei</dc:creator><dc:creator> Kayoko Tsuji</dc:creator><dc:creator> Shun Horaguchi</dc:creator><dc:creator> Mitsuru Komahashi</dc:creator><dc:creator>高什·奥希马（Takashi Oshima）</dc:creator><dc:creator> Tetsuro Sasada</dc:creator><dc:date> 2025-02-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>免疫细胞在胃癌患者的乳状乳白点中的特征和临床意义</dc:title><dc:identifier>PMID：39949777</dc:identifier><dc:identifier> PMC：PMC11821591</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1521278</dc:identifier></item><item><title>二硫酸二硫酸菌是胶质母细胞瘤进展和免疫细胞损害的关键调节剂</title><link/>https://pubmed.ncbi.nlm.nih.gov/39949776/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250214071914&amp;v=2.18.0.post9+e462414<description>结论：二硫代基因基因在胶质母细胞瘤进展和免疫相互作用中是关键的，为通过调节T细胞耗尽的调节提供了改善抗Glioblastoma疗法的新途径。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月30日； 16：1526296。 doi：10.3389/fimmu.2025.1526296。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：胶质母细胞瘤与预后不良和免疫功能受损相关，显示了新鉴定的二硫代病机制与T细胞衰竭之间的潜在相互作用，但这些含量仍被研究了。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：使用LASSO回归鉴定关键基因，然后进行多变量分析以开发预后模型。单细胞伪颞分析探索了细胞分化中的二硫代菌T细胞耗尽（TEX）信号传导。通过SSGSEA评估了免疫浸润，而Transwell分析和免疫荧光检查了二硫代基基因基因对神经胶质瘤细胞行为和免疫反应的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：发现十一二硫代基因基因对胶质母细胞瘤的生存结果至关重要。该基因集为预测患者预后的模型基础。单细胞分析显示内皮细胞中的二二硫酸二硫酸氢菌活性高。记忆T细胞种群与这些基因有关。 SMC4抑制作用降低了LN299细胞迁移并提高化学疗法敏感性，降低了CD4和CD8 T细胞激活。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：二硫代基因基因在胶质母细胞瘤进展和免疫相互作用中是关键的，为通过调节T细胞耗尽的调节提供了改善抗胶质母细胞瘤疗法的新途径。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39949776/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">39949776</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11821639/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">PMC11821639</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1526296>10.3389/fimmu.2025.1526296</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39949776</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> yifu shu</dc:creator><dc:creator> Jing li</dc:creator><dc:date> 2025-02-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>二硫酸二硫酸菌是胶质母细胞瘤进展和免疫细胞损害的关键调节剂</dc:title><dc:identifier>PMID：39949776</dc:identifier><dc:identifier> PMC：PMC11821639</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1526296</dc:identifier></item><item><title>非小细胞肺癌患者中&lt;em>; pcdhgb7 &lt;em>; pcdhgb7的甲基化和表达</title><link/>https://pubmed.ncbi.nlm.nih.gov/39949775/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250214071914&amp;v=2.18.0.post9+e462414<description>结论：PCDHGB7表达和甲基化是非小细胞肺癌中的预后和免疫生物标志物。血浆PCDHGB7甲基化和蛋白质水平可用作预测免疫疗法在肺癌中的疗效的新型生物标志物。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月30日； 16：1516628。 doi：10.3389/fimmu.2025.1516628。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：原钙粘蛋白B，7（PCDHGB7）是原钙粘蛋白家族的成员，在神经元连接中起关键作用，并且与女性生殖系统癌症有关。它在肺癌中的功能尚未阐明。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们通过公共数据集（HPA，TCGA，GEO，ONCODB和MEXPRESS）全面研究了PCDHGB7表达，预后，生物学功能，甲基化模式，及其与免疫浸润和免疫疗法反应的关系。从我们的临床中心招募了两个肺癌免疫疗法队列，以检测血浆中<i>PCDHGB7</i>的甲基化与蛋白质水平之间的关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在肺腺癌（LUAD）和肺鳞状细胞癌（LUSC）中， <i>PCDHGB7</i>表达下调，并与肿瘤预后有关。 <i>PCDHGB7</i>与抑制性免疫细胞有正相关，与肿瘤突变负担（TMB）和同源重组缺乏（HRD）的负相关。 <i>PCDHGB7</i>的甲基化水平在肿瘤组织中上调，与<i>PCDHGB7</i> mRNA水平负相关。在免疫疗法队列研究中， <i>PCDHGB7</i>组织表达较高的患者的预后较差。基线等离子体中<i>PCDHGB7</i>高甲基化的患者的无进展生存期（PFS）较短和总生存期（OS），而<i>PCDHGB7</i>甲基化早期降低的患者的预后最佳。血浆<i>PCDHGB7</i>蛋白水平可以预测对免疫检查点抑制剂的反应，并作为PFS的预后标记。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论： <i>PCDHGB7</i>表达和甲基化是非小细胞肺癌中的预后和免疫生物标志物。血浆<i>PCDHGB7</i>甲基化和蛋白质水平可用作预测免疫疗法在肺癌中的疗效的新型生物标志物。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39949775/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">39949775</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11821955/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">PMC11821955</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1516628>10.3389/fimmu.2025.1516628</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39949775</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Yue Yuan</dc:creator><dc:creator> XIN NIE</dc:creator><dc:creator> Jiayi Gao</dc:creator><dc:creator> Yumeng Tian</dc:creator><dc:creator> Liuer他</dc:creator><dc:creator>Xue Wang</dc:creator><dc:creator>张张</dc:creator><dc:creator>马林·马林</dc:creator><dc:creator>林李</dc:creator><dc:date>2025-02-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>非小细胞肺癌患者中&lt;em>; pcdhgb7 &lt;em>; pcdhgb7的甲基化和表达</dc:title><dc:identifier>PMID：39949775</dc:identifier><dc:identifier> PMC：PMC11821955</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1516628</dc:identifier></item><item><title>叉质：亚型特异性人内源性逆转录病毒K102包膜蛋白是一种新型的血清免疫抑制癌症</title><link/>https://pubmed.ncbi.nlm.nih.gov/39949774/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250214071914&amp;v=2.18.0.post9+e462414<description> [这纠正了文章doi：10.3389/fimmu.2024.1533740。]。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月30日； 16：1560546。 doi：10.3389/fimmu.2025.1560546。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> [这纠正了文章doi：10.3389/fimmu.2024.1533740。]。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39949774/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">39949774</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11822254/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">PMC11822254</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1560546>10.3389/fimmu.2025.1560546</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39949774</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Qinyuan Gong</dc:creator><dc:creator> Rongzhen Xu</dc:creator><dc:date> 2025-02-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>叉质：亚型特异性人内源性逆转录病毒K102包膜蛋白是一种新型的血清免疫抑制癌症</dc:title><dc:identifier>PMID：39949774</dc:identifier><dc:identifier> PMC：PMC11822254</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1560546</dc:identifier></item><item><title>用于治疗MS和NMOSD复发的格言：抗体反应率降低，基因表达变化和潜在的临床反应指标</title><link/>https://pubmed.ncbi.nlm.nih.gov/39949773/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250214071914&amp;v=2.18.0.post9+e462414<description>结论：我们的数据表明，MS中的治疗格式迅速导致IgG反应率对EBNA1（391-410）（391-410）和交叉反应靶标（例如GlialCam（370-389））显着降低，并且对B的基因表达也有影响细胞和T细胞。需要进一步的研究来验证抗EBNA1（391-410）抗体反应率以及与CD4-CTL相关基因的表达是否可能表明对该疗法的个体临床反应。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月30日； 16：1531447。 doi：10.3389/fimmu.2025.1531447。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：高剂量的糖皮质激素是多发性硬化症（MS）或神经肌炎选择性谱系障碍（NMOSD）患者急性复发的标准治疗方法。可以考虑使用治疗性的疗程来升级复发疗法，但有些患者仍然没有足够的康复。我们旨在探索格言对体液和细胞免疫参数的影响，并确定与有益临床结果相关的特征。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们研究了两个人群，其中包括63例MS或NMOSD患者，他们正在接受甲基泼尼松龙或分离术接受复发治疗。在治疗前后收集血液样本以分离血浆或血清以及免疫细胞。然后，我们测量了（1）免疫球蛋白同型IgG，IgM和IgA的浓度，（2）抗源自源自潜在自身抗原和Epstein-Barr病毒蛋白的肽的抗体反应性，（3）CD19 <sup>+</sup> B细胞的频率，CD3 <sup>+</sup> T细胞的频率和CD14 <sup>+</sup>单核细胞，（4）CD19 <sup>+</sup> B细胞和CD4 <sup>+</sup> T细胞的转录组轮廓以及（5）CD4 <sup>+</sup> T细胞中7个细胞毒性相关基因的mRNA水平。将数据与治疗中的变化以及临床反应者和非反应者之间的差异进行了比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：用甲基苯甲甲酮的初始疗法对免疫球蛋白水平和（自动）抗体反应率没有显着影响（ <i>N</i><sub>最大</sub>= 27 ms患者）。相比之下，接受置换术的MS患者（ <i>N</i> <sub>MAX</sub> = 27）显示出强烈的免疫球蛋白降低率，尤其是IgG，并且针对所有测试肽的抗体反应率降低。 EBNA1（氨基酸391-410）是唯一达到NMOSD患者显着性水平的肽（ <i>n</i> = 9）。在基线时，对格言（ <i>n</i> = 12）的非反应（n = 12）的平均具有更高的抗EBNA1（391-410）反应率（ <i>n</i> = 24）。格言也导致单核细胞比例降低，T细胞比例（ <i>n</i> = 29例MS或NMOSD患者）和中等转录组变化（ <i>N</i> <sub>MAX</sub> = 4 ms患者）的比例增加。发现在非反应器中基线时，基因表达特征是CD4 <sup>+</sup>细胞毒性T淋巴细胞（CD4-CTL）的特征，尽管无法以统计学显着性验证（ <i>n</i> = 19 MS患者）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们的数据表明，MS中的治疗格式迅速导致IgG反应率对EBNA1（391-410）（391-410）和交叉反应靶标（例如GlialCam（370-389））显着降低，并且对B的基因表达也有影响细胞和T细胞。需要进一步的研究来验证抗EBNA1（391-410）抗体反应率以及与CD4-CTL相关基因的表达是否可能表明对该疗法的个体临床反应。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39949773/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">39949773</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11821495/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">PMC11821495</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1531447>10.3389/fimmu.2025.1531447</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39949773</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator>迈克尔·赫克（Michael Hecker）</dc:creator><dc:creator>英国菲茨纳</dc:creator><dc:creator>ISIS路德维格 - 葡萄酒</dc:creator><dc:creator>Friederike Bohne</dc:creator><dc:creator>埃德玛·海兰（Edmar Heyland）</dc:creator><dc:creator>朱利安·克莱梅特（Juliane Klehmet）</dc:creator><dc:creator> Matthias Grothe</dc:creator><dc:creator>马蒂亚斯·施瓦布（Matthias Schwab）</dc:creator><dc:creator>亚历山大·温克尔曼（Alexander Winkelmann）</dc:creator><dc:creator> Stefanie Meister</dc:creator><dc:creator>艾尔斯·杜德塞克（Ales Dudesek）</dc:creator><dc:creator>汉娜·沃姆（Hannah Wurm）</dc:creator><dc:creator>伊利亚·艾森伯格（Ilya Ayzenberg）</dc:creator><dc:creator> Ingo Kleiter</dc:creator><dc:creator>科琳娜·特雷布斯特（Corinna Trebst）</dc:creator><dc:creator> MartinWhümmert</dc:creator><dc:creator>伯恩哈德·诺伊曼（Bernhard Neumann）</dc:creator><dc:creator>克劳斯·尤利茨（Klaus Eulitz）</dc:creator><dc:creator> Dirk Koczan</dc:creator><dc:creator> Uwe K Zettl</dc:creator><dc:date> 2025-02-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>用于治疗MS和NMOSD复发的格言：抗体反应率降低，基因表达变化和潜在的临床反应指标</dc:title><dc:identifier>PMID：39949773</dc:identifier><dc:identifier> PMC：PMC11821495</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1531447</dc:identifier></item><item><title> Chromatin accessibility and differentially expressed genes profiling in large yellow croaker (&lt;em>;Larimichthys crocea&lt;/em>;) head kidney cells following iridovirus infection</title><link/> https://pubmed.ncbi.nlm.nih.gov/39949772/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250214071914&amp;v=2.18.0.post9+e462414<description> INTRODUCTION: The large yellow croaker iridovirus (LYCIV) poses a significant threat to the aquaculture industry of Larimichthys crocea. Understanding the host defense response to LYCIV infection is crucial for developing effective strategies to mitigate its impact. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Jan 30;16:1513966. doi: 10.3389/fimmu.2025.1513966.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTRODUCTION: The large yellow croaker iridovirus (LYCIV) poses a significant threat to the aquaculture industry of <i>Larimichthys crocea</i> . Understanding the host defense response to LYCIV infection is crucial for developing effective strategies to mitigate its impact. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: In this study, an epigenetic approach was employed to investigate dynamic changes in chromatin accessibility using the assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq). Additionally, RNA sequencing (RNA-seq) was used to analyze the expression pattern of immune response genes upon LYCIV infection. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Substantial alterations in chromatin accessibility were observed, particularly in the regulatory regions of key immune-related genes. Significant changes in the expression of AP-1 transcription factors, including the <i>Batf</i> gene, were noted. CUT&amp;Tag results revealed that AP-1 was significantly enriched in the open chromatin regions of cytokine genes, with <i>Batf</i> potentially regulating the cytokine genes <i>LIF</i> and <i>CLCF1</i> . </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DISCUSSION: These findings suggest that AP-1 may play a crucial role in the defense response against viral infection by modulating inflammatory cytokines and contributing to cellular inflammatory responses. This study provides a comprehensive analysis of the epigenomic landscape and gene expression regulation during iridovirus infection in <i>L. crocea</i> , offering valuable insights for breeding programs aimed at combating iridovirus infections.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39949772/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">39949772</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11821590/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">PMC11821590</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1513966>10.3389/fimmu.2025.1513966</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39949772</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Chaowei Song</dc:creator><dc:creator> Ying Huang</dc:creator><dc:creator> Fang Han</dc:creator><dc:creator> Zhiyong Wang</dc:creator><dc:date> 2025-02-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>Chromatin accessibility and differentially expressed genes profiling in large yellow croaker (&lt;em>;Larimichthys crocea&lt;/em>;) head kidney cells following iridovirus infection</dc:title><dc:identifier> pmid:39949772</dc:identifier><dc:identifier> pmc:PMC11821590</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1513966</dc:identifier></item><item><title> Tocilizumab modulates the activity of the classical and alternative complement pathways in rheumatoid arthritis patients</title><link/> https://pubmed.ncbi.nlm.nih.gov/39949771/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250214071914&amp;v=2.18.0.post9+e462414<description> CONCLUSION: TCZ reduces the activity of the classical and alternative pathways of the complement system in RA patients regardless of the improvement in disease activity. This finding may contribute to a better understanding of the mechanisms by which the IL-6 blockade reduces disease activity in RA patients. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Jan 30;16:1486588. doi: 10.3389/fimmu.2025.1486588.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Tocilizumab (TCZ) is a monoclonal antibody that neutralizes interleukin (IL)-6 and is indicated for diseases characterized by markedly elevated inflammatory markers, such as rheumatoid arthritis (RA). The complement system has been implicated in the etiopathogenesis of RA. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: To evaluate the effect of systemic IL-6 inhibition on complement pathways functional activity in RA patients treated with TCZ. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DESING: Prospective non-interventional study. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Twenty-seven RA patients included in the TOCRIVAR study who received TCZ (8mg/kg IV/q4w) were evaluated at baseline and at weeks 12, 24 and 52 of treatment. Disease activity, as assessed by composite indices, acute phase reactants, and new-generation functional assays of the three complement pathways, was evaluated at baseline and at each follow-up visit. Multivariable linear mixed models were used to determine changes in the complement system cascades over time. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: After adjustment for disease activity, basal levels of the classical and alternative pathways decreased significantly after TCZ treatment. The effect on the classical pathway remained significant after 52 weeks. The decrease in the alternative pathway was significant at weeks 12 and 24, but not at week 52 of TCZ treatment. TCZ had no effect on the lectin cascade throughout the follow-up. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: TCZ reduces the activity of the classical and alternative pathways of the complement system in RA patients regardless of the improvement in disease activity. This finding may contribute to a better understanding of the mechanisms by which the IL-6 blockade reduces disease activity in RA patients.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39949771/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">39949771</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11821478/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">PMC11821478</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1486588>10.3389/fimmu.2025.1486588</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39949771</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Iván Ferraz-Amaro</dc:creator><dc:creator> Sergio Santos-Concepción</dc:creator><dc:creator> Javier Castro-Hernández</dc:creator><dc:creator> Maria Vanesa Hernández-Hernández</dc:creator><dc:creator> Beatriz Tejera Segura</dc:creator><dc:creator> Cristina Luna</dc:creator><dc:creator> Esmeralda Delgado-Frias</dc:creator><dc:creator> Federico Díaz-González</dc:creator><dc:date> 2025-02-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>Tocilizumab modulates the activity of the classical and alternative complement pathways in rheumatoid arthritis patients</dc:title><dc:identifier> pmid:39949771</dc:identifier><dc:identifier> pmc:PMC11821478</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1486588</dc:identifier></item><item><title> Preoperative assessment of liver regeneration using T1 mapping and the functional liver imaging score derived from Gd-EOB-DTPA-enhanced magnetic resonance for patient with hepatocellular carcinoma after hepatectomy</title><link/> https://pubmed.ncbi.nlm.nih.gov/39949770/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250214071914&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: T1 mapping parameters and FLIS were the potential noninvasive indicators of liver regeneration, except for HCC patients undergoing major hepatectomy. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Jan 30;16:1516848. doi: 10.3389/fimmu.2025.1516848.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVES: To explore whether T1 mapping parameters and the functional liver imaging score (FLIS) based on Gd-EOB-DTPA MRI could evaluate liver regeneration after hepatectomy for HCC patient. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: This retrospective study finally included 60 HCC patients (48 men and 12 women, with a median age of 53 years). T1 relaxation time of liver before gadoxetic acid injection (T1 <sub>pre</sub> ) and during the hepatobiliary phase (T1 <sub>HBP</sub> ), reduction rate (Δ%) and FLIS were calculated, their correlations with liver fibrosis stage, hepatic steatosis, and liver regeneration, quantified as regeneration index (RI), were assessed by Kendall&#39;s tau-b correlation test or Spearman&#39;s correlation test. Multivariate linear regression analyses were used to explore the indicator of RI. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: T1 <sub>pre</sub> , T1 <sub>HBP</sub> , Δ%, and FLIS manifested significant correlation with fibrosis stage (r = 0.434, <i>P</i> =0.001; r = 0.546, <i>P</i> &lt; 0.001; r = -0.356, <i>P</i> =0.005; r = -0.653, <i>P &lt;</i> 0.001, respectively). T1 <sub>pre</sub> showed significant correction with steatosis grade (r = 0.415, <i>P</i> =0.001). Fibrosis stage and steatosis grade were associated with RI (r = -0.436, <i>P</i> &lt;0.001; r = -0.338, <i>P</i> =0.008). Accordingly, T1 <sub>pre</sub> , T1 <sub>HBP</sub> and FLIS were the significant predictors ( <i>P</i> &lt;0.05) of RI in multivariate analysis. Similarly, in the patients undergoing minor hepatectomy (n=35), T1 <sub>HBP</sub> , Δ% and FLIS were related to RI ( <i>P</i> &lt;0.05) in multivariate analysis. Nevertheless, in the patients undergoing major hepatectomy (n=25), no T1 mapping parameter and FLIS was the independent predictor of RI. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: T1 mapping parameters and FLIS were the potential noninvasive indicators of liver regeneration, except for HCC patients undergoing major hepatectomy. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CLINICAL RELEVANCE STATEMENT: The value of T1 mapping and FLIS with Gd-EOB-DTPA MRI for accurate preoperative evaluation of liver regeneration is critical to prevent liver failure and improve prognosis of HCC patients.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39949770/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">39949770</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11821634/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">PMC11821634</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1516848>10.3389/fimmu.2025.1516848</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39949770</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator>列李</dc:creator><dc:creator>Tong Zhang</dc:creator><dc:creator> Shan Yao</dc:creator><dc:creator> Feifei Gao</dc:creator><dc:creator> Lisha Nie</dc:creator><dc:creator> Hehan Tang</dc:creator><dc:creator> bin歌曲</dc:creator><dc:creator>是的</dc:creator><dc:date>2025-02-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>Preoperative assessment of liver regeneration using T1 mapping and the functional liver imaging score derived from Gd-EOB-DTPA-enhanced magnetic resonance for patient with hepatocellular carcinoma after hepatectomy</dc:title><dc:identifier> pmid:39949770</dc:identifier><dc:identifier> pmc:PMC11821634</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1516848</dc:identifier></item><item><title> Correlations between primary tumour location, biomarkers of inflammation and lung injury, and postoperative pulmonary complications in patients underwent laparoscopic colorectomy: a propensity score matched analysis of 300 patients</title><link/> https://pubmed.ncbi.nlm.nih.gov/39949769/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250214071914&amp;v=2.18.0.post9+e462414<description> CONCLUSION: The primary site of CRC is an independent predictor of the development of PPCs. Despite the steep Trendelenburg position of the RSC group inciting more pulmonary stress, inflammation and lung epithelial injury, as indicated by higher sRAGE, it demonstrated a lower PPCs occurrence relative to its DAC counterpart, with a slightly inclined or reversed Trendelenburg position. None of the plasma biomarkers of inflammation or lung injury indicated sufficient prognostic value for PPCs. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Jan 30;16:1546167. doi: 10.3389/fimmu.2025.1546167.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTRODUCTION: The impact of distinct primary colorectal cancer (CRC) sites on lung injury and complications remains largely unexplored, despite the palpable differences in surgical positions, procedures, and the resulting mechanically induced respiratory pressures at each site. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MATERIALS AND METHODS: This study employed a forwards-looking approach utilising the propensity score matching (PSM) method; 300 patients with pathological CRC after laparoscopic surgery from April 2019 to May 2023 were enrolled. Two categories were bifurcated based on their surgical locations: the rectosigmoid colon (RSC) group and the descending/ascending colon (DAC) group, with a 2:1 ratio. The occurrence of postoperative pulmonary complications (PPCs) within a 30-day postoperative period was meticulously evaluated. Additionally, assessments have been performed for plasma biomarkers of immune response dynamics and lung injury (plasma soluble advanced glycation end-product receptor [sRAGE], angiopoietin-2 [ANG-2], interleukin-1β/6 [IL-1β/IL-6]) and other parameters. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Although the increase in postoperative lung epithelial damage, as indicated by the plasma sRAGE levels, was significant in the RSC group (DAC vs. RSC; 1029.6 [576.8-1365.2] vs. 1271.6 [896.3-1587.6]; odds ratio=0.999; 95% CI: 0.998 to 1.000; P=0.007), a significantly increased percentage of PPCs was observed in the DAC group (DAC vs. RSC; hazard ratio=1.669; 95% CI, 1.141 to 2.439; P=0.008). A univariate Cox proportional hazards model revealed that sRAGE, ANG-2, IL-1β, and IL-6 levels were not correlated with the incidence of time-to-PPCs across the two cohorts (P>;0.05). Propensity score-weighted Cox regression and causal mediation analysis further demonstrated that the DAC site directly affected the incidence of PPCs, regardless of the other baseline confounders and clinical covariates related to the tumour site and PPCs. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: The primary site of CRC is an independent predictor of the development of PPCs. Despite the steep Trendelenburg position of the RSC group inciting more pulmonary stress, inflammation and lung epithelial injury, as indicated by higher sRAGE, it demonstrated a lower PPCs occurrence relative to its DAC counterpart, with a slightly inclined or reversed Trendelenburg position. None of the plasma biomarkers of inflammation or lung injury indicated sufficient prognostic value for PPCs.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39949769/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">39949769</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11821553/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250214071914&v=2.18.0.post9+e462414">PMC11821553</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1546167>10.3389/fimmu.2025.1546167</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39949769</guid><pubDate> Fri, 14 Feb 2025 06:00:00 -0500</pubDate><dc:creator> Hui-Xian Li</dc:creator><dc:creator>李切</dc:creator><dc:creator>Yuan Li</dc:creator><dc:creator> Tai-Hang Wang</dc:creator><dc:creator> Fang-di Min</dc:creator><dc:creator> Lei Xu</dc:creator><dc:creator> Meng Wang</dc:creator><dc:creator> Zhao-Xu Zheng</dc:creator><dc:creator> Shi-Ning Qu</dc:creator><dc:creator> Fei Wang</dc:creator><dc:creator> Wei Tang</dc:creator><dc:creator> Shi-Jing Wei</dc:creator><dc:creator> Yu-Lin Sun</dc:creator><dc:creator> Hui Zheng</dc:creator><dc:creator>陶</dc:creator><dc:date>2025-02-14</dc:date><dc:source>免疫学领域</dc:source><dc:title>Correlations between primary tumour location, biomarkers of inflammation and lung injury, and postoperative pulmonary complications in patients underwent laparoscopic colorectomy: a propensity score matched analysis of 300 patients</dc:title><dc:identifier> pmid:39949769</dc:identifier><dc:identifier> pmc:PMC11821553</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1546167</dc:identifier></item></channel></rss>